Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, classical Hodgkin lymphoma, colorectal cancer, gastroesophageal cancer, hepatocellular cancer, and other solid tumors. 31584451 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Coprimary endpoints were investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival, assessed in the intention-to-treat population and in patients with PD-L1 immune cell-positive tumours (tumours with ≥1% PD-L1 expression). 31786121 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors. 31500267 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE <b>Purpose:</b> We conducted this study to determine the relationship between PD-1/PD-L1 inhibitors and the incidence risk of peripheral neuropathy in patients with solid tumors. 31552184 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Recently, US Food and Drug Administration approved anti-PD-L1 immunotherapy for solid tumors with deficient mismatch repair (MMR). 30633926 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. 30515672 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE However, the response rates of anti-PD-L1 have been limited in several solid tumors. 31668929 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE This study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors. 31230047 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Immune checkpoint inhibitors such as anti-cytotoxic T lymphocyte antigen-4 or anti-programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have demonstrated durable response rates across a broad range of solid tumors, including NSCLC, which has revolutionized the treatment of solid tumors. 30612418 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Our findings also suggest TET activity as a biomarker for predicting the efficacy and patient response to anti-PD-1/PD-L1 therapy, and stimulating TET activity as an adjuvant immunotherapy of solid tumors. 31310587 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). 31046082 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 GeneticVariation phenotype BEFREE Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors are widely used in many types of solid tumors, and are often considered to be in the same immunotherapy subclass. 30698054 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE PD-1/PD-L1 expression on B cell subsets, as well as their signaling and inhibitory functions in solid tumors will be discussed in this review with the focus on how B cells expressing PD-1/PD-L1 play immunosuppressive roles in tumor progression, aiming to figure out the potential for development of diagnostic tools and new therapies involving this unique group of cells. 31250021 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Efficient silencing of CD47 and PD-L1 versus single gene silencing in vivo by systemic administration of LPP-P4-Ep could significantly inhibited the growth of solid tumors in subcutaneous and reduced lung metastasis in lung metastasis model. 30878596 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. 31607917 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE KEYNOTE-028 ( ClinicalTrials.gov identifier: NCT02054806) is a nonrandomized, phase Ib trial that enrolled 475 patients with PD-L1-positive advanced solid tumors who were treated with pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity occurred. 30557521 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Programmed cell death ligand 1 (PD-L1) expression has been shown to associate with poor prognosis in a variety of solid tumors. 31143091 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Eligible patients regardless of line of therapy had measurable disease by Response Evaluation Criteria in Solid Tumors, version 1.1; Eastern Cooperative Oncology Group performance status of 0 to 1; and a representative tumor sample for assessment of immune cell (IC) PD-L1 expression. 30242306 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Prespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety. 30676622 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE We included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases. 31796119 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. 30770348 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Meanwhile, the FDA approved PD-1/PD-L1 inhibition treatment for any solid tumor showing MSI and/or defects in the MMR system. 30650417 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Combination therapy with an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1) and an agent targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) is expected to be a novel and effective treatment option for various solid tumors including non-small cell lung cancer (NSCLC). 30642449 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE BACKGROUND Targeting of PD-1/PD-L1 immune checkpoints exhibits excellent clinical outcomes in numerous types of solid tumors, including gastric cancer. 31519868 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors. 30851544 2019